Advertisement

Tumor Biology

, Volume 35, Issue 4, pp 3327–3331 | Cite as

Serum levels of macrophage migration-inhibitory factor (MIF) have diagnostic, predictive and prognostic roles in epithelial ovarian cancer patients

  • Faruk Tas
  • Senem Karabulut
  • Murat Serilmez
  • Rumeysa Ciftci
  • Derya Duranyildiz
Research Article

Abstract

Macrophage migration-inhibitory factor (MIF) plays an important role in the pathogenesis of multiple malignancies, and its expression strongly also affects outcomes of cancer patients. The objective of this study was to determine the clinical significance of serum levels of MIF in epithelial ovarian cancer (EOC) patients. A total of 50 patients with a pathologically confirmed diagnosis of EOC were enrolled into this study. Serum MIF concentrations were determined using the solid-phase sandwich ELISA method. Age- and sex-matched 30 healthy controls were included in the analysis. Median age of patients was 56.5 years old, range 22 to 83 years. Majority of the patients had an advanced disease (International Federation of Gynecologists and Obstetricians (FIGO) stages III and IV) (90 %). Baseline serum MIF levels were significantly higher than those in the healthy control group (p = 0.005). No known clinical variables including histology, grade of histology, stage of disease, debulking surgery, and serum CA 125 levels were found to be correlated with serum MIF levels (p > 0.05). Only those chemotherapy-unresponsive patients had higher serum MIF levels compared with responsive ones (p = 0.02). Patients with elevated serum MIF concentrations had significantly unfavorable overall survival compared to those with lower levels (p = 0.01). However, a serum MIF level was found to play no prognostic role for progression-free survival (p = 0.09). In conclusion, serum levels of MIF have diagnostic, predictive, and prognostic roles in EOC patients.

Keywords

Serum MIF Ovarian cancer Prognostic factor 

Notes

Conflicts of interest

None

References

  1. 1.
    Babu SN, Chetal G, Kumar S. Macrophage migration inhibitory factor: a potential marker of cancer diagnosis and therapy. Asian J Cancer Prev. 2012;13:1737–44.CrossRefGoogle Scholar
  2. 2.
    Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H, Balkwill FR. Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cancer Ther. 2007;6:1993–2002.PubMedCrossRefGoogle Scholar
  3. 3.
    Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, et al. Macrophages induce invasiveness of epithelial cancer cells via NF-κB and JNK. J Immunol. 2005;175:1197–205.PubMedGoogle Scholar
  4. 4.
    Wu HM, Zhu SL, He LJ, Liu YH, Xie D. Clinical significance of macrophage migration inhibitory factor in invasion of ovarian cancer. Ai Zheng. 2009;28:1054–60 (article in Chinese).PubMedGoogle Scholar
  5. 5.
    Krockenberger M, Dombrowski Y, Weidler C, Ossadnik M, Hönig A, Hausler S, et al. Macrophage migration inhibitory factor (MIF) contributes to the immune escape of ovarian cancer by downregulating NKG2D. J Immunol. 2008;180:7338–48.PubMedCentralPubMedGoogle Scholar
  6. 6.
    Agarwal R, Whang DH, Alvero AB, Visintin I, Lai Y, Segal EA, et al. Macrophage migration inhibitory factor expression in ovarian cancer. Am J Obstet Gynecol. 2007;196:348.e1–348e5.Google Scholar
  7. 7.
    Krockenberger M, Kranke P, Hausler S, Engel JB, Horn E, Nürnberger K, et al. Macrophage migration-inhibitory factor levels in serum of patients with ovarian cancer correlates with poor prognosis. Anticancer Res. 2012;32:5233–8.PubMedGoogle Scholar
  8. 8.
    He G, Holcroft CA, Beauchamp MC, Yasmeen A, Ferenczy A, Kendall-Dupont J, et al. Combination of serum biomarkers to differentiate malignant from benign ovarian tumours. J Obstet Gynaecol Can. 2012;34:567–74.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Faruk Tas
    • 1
  • Senem Karabulut
    • 1
  • Murat Serilmez
    • 1
  • Rumeysa Ciftci
    • 1
  • Derya Duranyildiz
    • 1
  1. 1.Institute of OncologyUniversity of IstanbulIstanbulTurkey

Personalised recommendations